AGILeBiotics is a pharmaceutical company focusing on the development of novel antibiotics for the treatment of life-threatening infections by multidrug-resistant bacteria.

AGILeBiotics received a pre-seed investment from three regional investors, i.e. RUG Houdstermaatschappij B.V., Hanzepoort B.V., Stichting Ir. G.J. Smid Fonds. With this financial support, AGILeBiotics has started its drug discovery and development program.
In July 2018, Pharma Connect Capital B.V. and Carduso Capital B.V. joined as investors boosting our drug development program with the goal to bring our lead compounds into advanced pre-clinincal development.